2023
Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression
Pakasticali N, Chobrutskiy A, Patel D, Hsiang M, Zaman S, Cios K, Blanck G, Chobrutskiy B. Chemical Complementarity of Breast Cancer Resident, T-Cell Receptor CDR3 Domains and the Cancer Antigen, ARMC3, is Associated With Higher Levels of Survival and Granzyme Expression. Cancer Informatics 2023, 22: 11769351231177269. PMID: 37313373, PMCID: PMC10259117, DOI: 10.1177/11769351231177269.Peer-Reviewed Original ResearchCancer-testis antigensCancer antigensBreast cancer antigensT cell receptorGranzyme expressionImmune biomarkersCancer immunotherapyPatient outcomesGranzyme BCandidate antigensTestis antigensAdaptive immune receptorsAntigenCDR3 domainsImmune receptorsTumor gene expression dataReceptorsSurvivalAntigen bindingRegion 3Integration of itemsHigh levelsImmunotherapyBreast cancer datasetExpression correlation
2018
T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer
Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal Of Cancer Research And Clinical Oncology 2018, 145: 615-623. PMID: 30539280, DOI: 10.1007/s00432-018-2815-1.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell responsesBladder tumor tissuesT-cell featuresEx vivo amplificationT cell receptorBladder cancerCancer findingsFavorable outcomeCancer settingBetter outcomesSurvival rateTumor tissueCancerDriver mutationsImmunotherapyBiochemical featuresBioinformatics assessmentOutcomesAntigen bindingRegion 3TILsPatientsLymphocytesTherapy